-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2022-501966-23-00
5
2018-09-11
Resected High-Risk Stage II Melanoma
-
2022-501076-26-00
4
2018-08-28
high risk diffuse large B-cell lymphoma
-
2023-508018-41-00
4
2018-07-27
Primary Myelofibrosis (PMF), Post-polycythemia Vera or Post-essential
-
2022-501038-48-00
4
2018-07-26
Diffuse Large B-Cell Lymphoma
-
2024-511890-30-03
6
2018-06-26
Subfertility
-
2023-510556-22-00
4
2018-03-05
non-Hodgkin lymphoma (NHL)
-
2022-502798-40-00
5
2017-07-31
Patients with resected colon carcinoma
-
2024-516106-31-00
10
2017-06-16
Early stage colorectal cancer
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-511348-25-00
10
2015-12-11
Myelodysplastic syndromes (MDS)
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2023-503423-25-00
5
2014-06-19
Burkitt lymphoma
-
2023-503298-39-00
5
2024-06-13
Metastatic Non-Small Cell Lung Cancer (mNSCLC)
-
2024-520354-37-00
4
2025-09-08
Influenza disease
-
2024-515230-32-00
3
2024-10-09
Inflammatory Conditions
-
2022-501979-10-00
6
2024-08-08
Monkeypox
-
2023-510472-31-00
3
2024-07-05
Healthy Adult Participants
-
2023-506696-10-00
5
2024-06-18
Non-Small Cell Lung Cancer
-
2023-510196-59-00
5
2024-06-15
Respiratory Syncytial Virus Infections
-
2023-510467-35-00
3
2024-06-05
Healthy Adult Participants.
-
2023-507781-13-00
1
2024-05-24
Patients with relapsed/refractory acute myeloid leukemia or myelodyspl